Berg M, Uellner R, Langhorne J
Department of Biology, Imperial College of Science, Technology and Medicine, London, GB.
Eur J Immunol. 1997 Apr;27(4):1022-8. doi: 10.1002/eji.1830270432.
Here we show that the B cell lymphoma A20.292 is capable of enhanced antigen presentation to CD4+ T cells in the presence of specific antibodies. This enhancement was inhibited by anti-Fc gamma receptor (R) antibodies, suggesting that it might be due to preferential uptake of the antigen/antibody complex through the Fc gamma RII receptor. However, immunoprecipitation studies revealed that the FcR of A20.292 cells was of the B cell type, Fc gamma RIIb1, which is not thought to be able to internalize antigen/antibody complexes via clathrin-coated pits. It was considered unlikely that A20.292 had an altered form of the B cell Fc gamma R (RIIb1) receptor that enabled internalization, since similar enhancing effects were also observed using an Fc gamma RII cell line that had been transfected with Fc gamma RIIb1. To reconcile these findings with the expression of Fc gamma RIIb1, it is postulated that immune complexes are concentrated on the cell surface by the Fc gamma RIIb1 and are thus available for preferential uptake by random fluid-phase endocytosis. This results in more efficient generation of the epitopes recognized by these T cell hybridomas.
在此我们表明,在存在特异性抗体的情况下,B细胞淋巴瘤A20.292能够增强向CD4+ T细胞的抗原呈递。这种增强作用被抗Fcγ受体(R)抗体所抑制,这表明其可能是由于抗原/抗体复合物通过FcγRII受体的优先摄取。然而,免疫沉淀研究显示,A20.292细胞的FcR属于B细胞类型,即FcγRIIb1,一般认为它无法通过网格蛋白包被小窝内化抗原/抗体复合物。由于使用转染了FcγRIIb1的FcγRII细胞系也观察到了类似的增强作用,所以认为A20.292不太可能具有能实现内化的B细胞FcγR(RIIb1)受体的改变形式。为了使这些发现与FcγRIIb1的表达相协调,推测免疫复合物通过FcγRIIb1在细胞表面浓缩,从而可通过随机液相内吞作用被优先摄取。这导致这些T细胞杂交瘤识别的表位能更有效地产生。